Scholarlink

Background <p>Thrombotic complications are a leading cause of mortality in type 2 diabetes mellitus (T2DM). In resource-limited settings, identifying affordable and accessible predictive biomarkers is paramount for risk stratification. However, population-specific Mean Platelet Volume (MPV) thresholds and their cost-effectiveness in conflict settings remain unknown, hindering its implementation in guidelines.</p> Objectives <p>This study aimed to evaluate the discriminatory value of mean platelet volume (MPV) for thrombotic risk and propose a low-cost screening strategy for patients with type 2 diabetes mellitus (T2DM) in Yemen, a resource-limited conflict setting.</p> Design <p>A cross-sectional study.</p> Setting <p>Major hospitals in Aden Governorate, Yemen.</p> Participants <p>140 adult Yemeni patients with clinically diagnosed T2DM.</p> Interventions <p>Not applicable.</p> Primary and secondary outcome measures <p>The primary outcome was the predictive performance (sensitivity, specificity, area under the curve) of MPV for a composite thrombotic risk endpoint. The secondary outcome was the strength of correlation between MPV and glycemic control (HbA1c).</p> Results <p>MPV was significantly elevated in patients with poor glycemic control (HbA1c ≥ 7%). ROC analysis identified an MPV value of 11.5 fL as a robust predictor of thrombotic risk, with a sensitivity of 78% and a specificity of 85% (AUC = 0.82, 95% CI: 0.74–0.89). A strong positive correlation was found between HbA1c and MPV (<i>r</i> = 0.52, <i>p</i> &lt; 0.001), demonstrating a dose-response relationship across glycemic strata.</p> Conclusion <p>MPV ≥ 11.5 fL shows promise as a highly discriminatory, low-cost marker of thrombotic risk in Yemeni T2DM patients. We propose that routine MPV testing should be considered for integration into national diabetic guidelines in Yemen and similar conflict-affected settings. This evidence-based, low-cost strategy could contribute to improved preventive care and reduce the burden of thrombosis where resources are most scarce.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mean platelet volume as a Low-Cost discriminatory marker for thrombotic risk assessment in Yemeni type 2 diabetic patients: A proposal for Resource-Limited settings

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Naif Taleb Ali,
  • Radfan Saleh Abdullah,
  • Mansour Abdelnabi H. Mahdi,
  • Gamila Saleh Ali,
  • Hana Mohsen Ali

摘要

Background

Thrombotic complications are a leading cause of mortality in type 2 diabetes mellitus (T2DM). In resource-limited settings, identifying affordable and accessible predictive biomarkers is paramount for risk stratification. However, population-specific Mean Platelet Volume (MPV) thresholds and their cost-effectiveness in conflict settings remain unknown, hindering its implementation in guidelines.

Objectives

This study aimed to evaluate the discriminatory value of mean platelet volume (MPV) for thrombotic risk and propose a low-cost screening strategy for patients with type 2 diabetes mellitus (T2DM) in Yemen, a resource-limited conflict setting.

Design

A cross-sectional study.

Setting

Major hospitals in Aden Governorate, Yemen.

Participants

140 adult Yemeni patients with clinically diagnosed T2DM.

Interventions

Not applicable.

Primary and secondary outcome measures

The primary outcome was the predictive performance (sensitivity, specificity, area under the curve) of MPV for a composite thrombotic risk endpoint. The secondary outcome was the strength of correlation between MPV and glycemic control (HbA1c).

Results

MPV was significantly elevated in patients with poor glycemic control (HbA1c ≥ 7%). ROC analysis identified an MPV value of 11.5 fL as a robust predictor of thrombotic risk, with a sensitivity of 78% and a specificity of 85% (AUC = 0.82, 95% CI: 0.74–0.89). A strong positive correlation was found between HbA1c and MPV (r = 0.52, p < 0.001), demonstrating a dose-response relationship across glycemic strata.

Conclusion

MPV ≥ 11.5 fL shows promise as a highly discriminatory, low-cost marker of thrombotic risk in Yemeni T2DM patients. We propose that routine MPV testing should be considered for integration into national diabetic guidelines in Yemen and similar conflict-affected settings. This evidence-based, low-cost strategy could contribute to improved preventive care and reduce the burden of thrombosis where resources are most scarce.